NCT00724997View on ClinicalTrials.gov

Randomized, Double-blind, Placebo-controlled, Phase I Dose-escalation Study of Single Dose GHB01L1 in Healthy Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

48

Participants

Timeline

Start Date

March 31, 2007

Primary Completion Date

July 31, 2008

Study Completion Date

August 31, 2008

Conditions
Seasonal Human Influenza
Interventions
BIOLOGICAL

GHB01L1

Study medication administered as a single intranasal aerosol (520ul) at doses of 6.4 log10, 6.7 log10, 7.0 log10, 7.4 log10 and 7.7 log10 TCID50/volunteer

Trial Locations (1)

A-1090

Medical University Vienna, Vienna General Hospital, Dpmt. of Clinical Pharmacology, Vienna

Sponsors
All Listed Sponsors
lead

AVIR Green Hills Biotechnology AG

INDUSTRY

NCT00724997 - Randomized, Double-blind, Placebo-controlled, Phase I Dose-escalation Study of Single Dose GHB01L1 in Healthy Volunteers | Biotech Hunter | Biotech Hunter